Figure 1
(A) Bone marrow smear showing three blast cells, a promyelocyte, two segmented forms, an erythroblast (arrowhead) and a lymphocyte (double arrowheads). Wright-Giemsa ×1000. with DS and AMKL, +8 was present in a subpopulation of blasts only and therefore represents a secondary genetic change in leukemogenesis. The absence of +8 in other lineages does not necessarily imply their being normal, since the primary event is not known. In fact, current data from cell culture experiments, blast cell phenotype and gene rearrangement studies support involvement of an early hemopoietic cell capable of multilineage differentiation in AMKL associated with DS. 1 In TAM associated with DS, the abnormal proliferation of blast cells is linked to the presence of an extra copy of chromosome 21. Support for this contention is provided by cases of TAM in a phenotypically normal newborn with +21 mosaicism 4 and in two genetically normal neonates, 5 in whom the abnormal proliferating population also harbors +21. Although the clinical course of TAM is that of spontaneous resolution, around 25% of such patients will relapse as AMKL Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis TO THE EDITOR Idiopathic myelofibrosis (IM) is a chronic myeloproliferative syndrome with a low frequency of acute transformation (5-22%). 1 The most frequent types of acute leukemia (AL) observed in these patients are myeloblastic or myelomonocytic. 1 later on in life, usually within 3 years. 1 Conversely, DS with AMKL will, with rare exceptions including our case, give a history of TAM in the neonatal period. 6 Taken together, these observations suggest that accumulation of genetic events in addition to +21 may be responsible for subsequent relapse of TAM. The fact that karyotypic abnormalities 7 besides +21 are much more frequently encountered in AMKL than in TAM are consistent with this hypothesis. The present study shows that one such cytogenetic change, namely +8, occurs only as a secondary/evolutionary event in the leukemogenic process and that important primary genetic events related to development of AMKL in DS remains to be established. and lymphoblastic have occasionally been reported. On the contrary, the association of acute promyelocytic leukemia (APL) and IM has not been previously described (MEDLINE search from 1988 to 1998, keywords: acute promyelocytic leukemia, idiopathic myelofibrosis). In this report we describe a patient who developed APL 6.5 years after the diagnosis of IM.
SK
A 66-year-old woman was admitted to our hospital in June 1990 because of tiredness and itching. Physical examination revealed hepatomegaly and splenomegaly 5 cm and 8 cm, respectively, below the costal margins. Hematological counts were: hemoglobin (Hb) 127 g/l; white blood cell (WBC) count 18.5 × 10 9 /l (88% neutrophils, 6% lymphocytes, 1% eosinophils, 1% basophils, 1% metamyelocytes, 1% myelocytes) and platelet count 504 × 10 9 /l. Blood smear showed anisopoikilocytosis with tear-drop erythrocytes, as well as 1% erythroblasts. The leukocyte alkaline phosphatase score was 170 (n, 40-80) and the serum B 12 vitamin level 1408 pg/ml (n, 200-750). Blood chemistry only showed a high level of LDH (485 IU/l, normal up to 270). Bone marrow aspiration was dry tap. A bone marrow biopsy revealed a hypercellular marrow with marked hyperplasia of the granulopoietic progenitors, remarkable proliferation of megakaryocytes and sinusoid dilation. Reticulin stain was positive (rank II) and trichromic stain was negative. A bone marrow cytogenetic analysis was normal. Diagnosis of IM was performed and the patient did not receive any treatment since January 1996, when hydroxyurea (500 mg/day, p.o.) was given, because of marked increase in hepatosplenomegaly and a rise in the WBC count (45 × 10 9 /l). Total dose of hydroxyurea was 90 g. Hydroxyurea therapy was stopped in November 1996.
The patient was admitted to hospital in February 1997 because of malaise, anorexia and ecchymoses. Physical examination revealed pallor, ecchymoses on the legs, hepatomegaly and splenomegaly 5 cm and 11 cm, respectively, below the costal margins. WBC count was 9.2 × 10 9 /l, with 60% atypical promyelocytes with increased granularity and faggots, Hb 90 g/l, and platelet count 6 × 10 9 /l. The prothrombin activity, activated thromboplastin time and fibrinogen level were normal, and fibrin-split products were not detected. Bone marrow examination aspirate was difficult to perform and showed a complete infiltration by atypical promyelocytes. The incidence of AL as a terminal event in idiopathic myelofibrosis ranges from 5% to 22%. 1 Although in most cases AL is myeloblastic or myelomonocytic, 1 isolated cases of megakaryocytic, 3 lymphoblastic and erythroleukaemia 2 have been described. On a bibliographic search of the MEDLINE database from 1988 to 1998 no cases of APL transformation in patients with IM were found. Three possibilities might explain the association of APL and IM in this patient: first, a promyelocytic blast crisis of IM; second, APL secondary to the treatment with hydroxyurea; and third, APL as a second metachronic neoplasm.
Although from the data of our search no reports of promyelocytic blast crises in patients with IM have been reported, such a possibility cannot be excluded in this patient. Most of the reports of blasts in transformation concern individual cases and except for promyelocytes, involvement of all the other cell lines (myeloid, monocytic, megakaryocytic, erythroid and lymphoid) has been found.
In this case APL could be secondary to treatment with hydroxyurea, a chemotherapeutic agent that the patient received a year prior to the diagnosis of APL. Although it has generally been assumed that hydroxyurea carries less leukemogenic potential than other alkylating drugs, 4 recent case reports and series from the literature have suggested a possible association between hydroxyurea therapy and a higher risk of the development of AL in patients with polycythemia vera and essential thrombocythemia. These findings suggest that the risk for hydroxyurea therapy is similar to that of the alkylating agents or 32 P. However, secondary AL associated with hydroxyurea therapy occurs in patients with high cumulative doses of hydroxyurea and a preleukemic phase is usually present. Although recent studies have reported cases of patients with APL previously treated with other chemotherapeutic agents, such as etoposide 5 or with radiotherapy, 6, 7 we found no referred cases of secondary APL in patients treated with hydroxyurea (MEDLINE search from 1988 to 1998, keywords: acute promyelocytic leukemia, hydroxyurea). Contrary to other secondary AL, good response to therapy is a well known feature in patients with secondary APL. [5] [6] [7] Finally, due to the absence of references on APL in patients with IM or in patients previously treated with hydroxyurea, we cannot exclude the possibility that in this patient APL could be a second de novo neoplasm.
